Skip to main content

Dashboard Topics Interactive Map Market Exposure Explore AI Mode How It Works

Product

Dashboard
Timeline
Finance
Map
Sources
AI Mode

Explore

Search
Topics
Tags
Entities
How It Works
Developers

Account

Sign In
Create Account
Watchlist
Notifications

Company

About
Editorial Team
Methodology
Editorial Policy
Press
Corrections
Changelog

Stay informed

Get a daily briefing of the most important geopolitical events, narrative shifts, and market signals.

Subscribe to newsletter

Legal·Privacy·Terms·Cookies·Accessibility·Contact

NarrativeRadar is a decision-support intelligence tool. It is not a news outlet, fact-checker, or investment advisor.

Developed by

Redirecting... | NarrativeRadar

Dashboard
/Zydus to settle Mirabegron patent litigation with Astellas by paying $120 million

Zydus to settle Mirabegron patent litigation with Astellas by paying $120 million

Zydus to settle Mirabegron patent litigation with Astellas by paying $120 million

ArchivedVerified|2 articles|2 sources|1 blocks

Detected: Updated: Analyzed:

Healthcare Regulation

NarrativeRadar Analysis·Reviewed by M. Reyes

Reported Facts

Observable data points shared across all narratives

•Zydus has agreed to pay $120 million to Astellas.
•The settlement pertains to patent litigation over the drug Mirabegron.
•The dispute was located in the United States.

What Could Happen If...

▸If Zydus successfully completes the payment... Then the company may avoid further legal complications related to the patent.

Sign in to see all scenarios and signals.

Key Actors

Countries

🌍United States of America

Instruments

Organizations

🏛Astellas 🏛Zydus

Source Coverage

FINANCE

2 articles

More coverage on this story

Topic: US–China Economic Conflict
More on United States of America
More on Mirabegron
More on Astellas
More on Zydus

Signals

Single-block coverage

Related Events

▸Moderna stock rises over 10% after patent dispute settlementArchived ▸Sun Pharma Expands Global Reach with $11.75B Organon AcquisitionArchived ▸Gilead nears $2bn buyout of biotech Ouro MedicinesArchived ▸Eli Lilly Surges Past Estimates on Strong Zepbound and Mounjaro SalesArchived ▸Bayer offers $7.25bn to settle weedkiller cancer claims

Primary Sources (2)

FINANCEThe Hindu - BusinessZydus to settle Mirabegron patent litigation with Astellas by paying $120 million FINANCEBusiness Standard (India)Zydus agrees to pay $120 million to settle US patent dispute with Astellas

·

AI-assisted, editorially supervised

·

Based on 2 articles from 2 sources

Zydus has reached a settlement with Astellas regarding the patent litigation over Mirabegron, agreeing to pay $120 million. This settlement resolves ongoing legal disputes related to the patent rights of the drug in the United States.

Archived